| The Children's Hospital of Philadelphia Patent applications |
| Patent application number | Title | Published |
|---|
| 20130143951 | HUMANIZED TTC AND METHODS OF USE THEREOF - Compositions and methods for treating neurological diseases and disorders are disclosed. | 06-06-2013 |
| 20130096361 | Uniform field magnetization and targeting of therapeutic formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles. | 04-18-2013 |
| 20130078302 | Protein C Zymogen and Methods of Use Thereof to Prevent Cancer Metastases - Compositions and methods useful for the inhibition of cancer metastasis are disclosed. | 03-28-2013 |
| 20130035240 | Markers for Obesity and Methods of Use Thereof - Markers for obesity, particularly childhood obesity, are provided along with methods of use thereof. | 02-07-2013 |
| 20130030042 | NUCLEIC ACIDS FOR TARGETING MULTIPLE REGIONS OF THE HCV GENOME - Compositions and methods effective for modulating Hepatitis C viral infection are provided. | 01-31-2013 |
| 20130018454 | Small Diameter Vascular Graft Produced by a Hybrid Method - The present invention relates to a hybrid graft and methods of generating the hybrid graft. The hybrid graft comprises an exterior surface and a luminal surface. The luminal surface comprises a micropattern of grooves to which cells adhere and orient along. The exterior surface comprises electrospun microfibers wherein the microfibers provide mechanical properties to the graft. The hybrid graft is capable supporting endothelial cell attachment, endothelial cell alignment, cell proliferation, and maintaining their in vivo function. The graft of the invention can recapitulate the in vivo morphology and function of natural vascular endothelium. | 01-17-2013 |
| 20130011370 | Uniform Field Magnetization and Targeting of Therapeutic Formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles. | 01-10-2013 |
| 20120316295 | STEROID LIPID-MODIFIED POLYURETHANE AS AN IMPLANTABLE BIOMATERIAL, THE PREPARATION AND USES THEREOF - A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial. | 12-13-2012 |
| 20120308973 | KIT AND METHOD FOR PROMOTION OF POSITIVE ADJUSTMENT TO ILLNESS AND TRAUMA - A kit for use in promoting a patient's positive adjustment includes a plurality of module units, each module unit containing instructions for coping with a specific stress symptom, and a transitional object having a module unit receiver. The module unit receiver can receive one of the module units and deliver the instructions on the module unit to the patient. A method of promoting positive adjustment includes the steps of providing a patient with a transitional object and a plurality of module units, each module unit containing instructions for coping with a specific stress symptom, identifying a stress symptom, selecting a module unit having instructions for coping with the stress symptom and delivering the instructions on the selected module unit to the patient with the transitional object. | 12-06-2012 |
| 20120288895 | Compositions and Methods for Modulating Hemostasis Using Variant Forms of Activated Factor V - Methods for the treatment of coagulation disorders using Factor V/Va variants are provided. | 11-15-2012 |
| 20120251586 | LIGAND-SPECIFIC INHIBITION OF ATTACHMENT OF IMMUNE CELLS TO IMPLANTABLE BIOMATERIALS - Methods for protecting biomaterials comprise attaching CD47 or Ig domain thereof to the surface of the biomaterial, thereby inhibiting or reducing immune cell attachment and/or immune cell-mediated damage to the biomaterial. Also provided are kits for practicing these methods and the protected biomaterials. | 10-04-2012 |
| 20120141419 | Biodegradable Linkers for Molecular Therapies - A method and a composition for delivery of a biomaterial to an animal cell or a tissue, the composition includes (a) a biomaterial; (b) a biodegradable cross-linker portion having a hydrolyzable bond, wherein the biodegradable cross-linker portion is covalently bound to the biomaterial; and (c) a substrate, wherein the substrate is covalently bound to the biodegradable cross-linker portion, provided that the biodegradable cross-linker is adapted to hydrolyze by breaking the hydrolyzable bond and thereby release and deliver the biomaterial. A process of making the composition is also provided. | 06-07-2012 |
| 20120135382 | INDIVIDUALIZED MASTERY-BASED DRIVER TRAINING - Driver training methods, systems, and computer readable media are disclosed. A training method receives sensor information from a vehicle driven along a driving route by an individual, assesses performance of the individual based on the sensor information and an individual mastery level, and adjusts the individual mastery level based on the assessed performance of the individual. The method may be embodied in a computer readable media. A driver training system includes a receiver that receives vehicle sensor information associated with a vehicle being driven along a driving route by an individual and a processor coupled to the receiver that assesses performance of the individual based on the received sensor information and an individual mastery level and adjusts the individual mastery level based on the assessed performance of the individual. Driver training protocols and systems and methods for implementing and transforming driver training protocols are also disclosed. | 05-31-2012 |
| 20120089222 | Photo-Activated Attachment Of Cholesterol To Polyurethane Surfaces For Adhesion Of Endothelial Cells - A polymer is provided according to structure (I) wherein Y is a thiol-reactive group selected from one or more of the following moieties and Z is an ionogenic group selected from one or more of the following moieties. The surface of a polymeric substrate is modified by contacting the surface with a polymer according to structure II or structure III and exposing the surface to ultraviolet light. | 04-12-2012 |
| 20120022136 | Cellular Genes Regulated by HIV-1 Infection and Methods of Use Thereof - This invention provides cellular gene products which have anti-apoptotic activity in HIV-1 infected cells and provides agents for the inhibition of the cellular gene products. | 01-26-2012 |
| 20110263690 | Methods and Compositions for use in Gene Therapy for Treatment of Hemophilia - Provided are compositions of viruses, the viruses including a recombinant adeno-associated virus vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding a blood coagulation factor and accompanying 5′ and 3′ untranslated regions and a transcription termination sequence. | 10-27-2011 |
| 20110126303 | Modified Blood Clotting Factors And Methods Of Use - The invention provides compositions including modified blood clotting factors that have a non-native proteolytic cleavage site engineered into them allowing intracellular cleavage and secretion of an active form. The compositions are useful in the methods for treating a bleeding or clotting disorder. | 05-26-2011 |
| 20110076767 | MAGNETICALLY-DRIVEN BIODEGRADABLE GENE DELIVERY NANOPARTICLES FORMULATED WITH SURFACE-ATTACHED POLYCATIONIC COMPLEX - A particle including a matrix-forming agent and a polyelectrolyte-amphiphilic agent adduct wherein the polyelectrolyte-amphiphilic agent adduct is in physical communication with the matrix-forming agent. The particle further includes a coated magnetic field-responsive agent and a biomaterial. Methods of making the particle are provided. Also provided are methods of delivery of the biomaterial to a target cell or a target tissue including administering the particle having the matrix-forming agent, polyelectrolyte-amphiphilic agent adduct, the coated magnetic field-responsive agent and the biomaterial; providing a magnetic device associated with the target cell or the target tissue; applying a magnetic force to the particle; and guiding the particle toward the magnetic device by the magnetic force. | 03-31-2011 |
| 20100285469 | METHOD OF TUMOR SCREENING - A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., DNA) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor. | 11-11-2010 |
| 20100260780 | Uniform field magnetization and targeting of therapeutic formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage. | 10-14-2010 |
| 20100210015 | PHOTOCHEMICAL ACTIVATION OF SURFACES FOR ATTACHING BIOMATERIAL - A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell. | 08-19-2010 |
| 20100204674 | Magnetically-Controllable Delivery System for Therapeutic Agents - A magnetic delivery system for delivering a magnetizable particle to a location in a body, the device includes a magnetizable object implanted in the body, wherein the magnetizable object includes a plurality of segments distributed throughout the magnetizable object and wherein the segments are configured to provide a magnetic gradient for attracting the magnetizable particle and an external source of a magnetic field capable of (i) magnetizing the magnetizable particle and (ii) increasing a degree of magnetization of the magnetizable object and thereby creating the magnetic gradient. A drug delivery system including the magnetic delivery system and a magnetizable particle associated with a therapeutic agent and/or a cell. A cell delivery system based on the magnetic delivery system and a magnetizable particle associated with a cell. A method of using the magnetic delivery system for delivery of a therapeutic agent and/or a cell to a targeted location in a body. | 08-12-2010 |
| 20100061984 | COMPOSITIONS AND METHODS FOR MODULATION OF SUPPRESSOR T CELL ACTIVATION - Methods of treating autoimmune disorders, coronary artery disease, allergy symptoms, allograft rejection sepsis/toxic shock are disclosed. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3 in combination with a T suppressor stimulus and/or an antigen. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3. Some methods comprise administering soluble GITR or antibodies that bind to GITR ligand. Methods of treating cancer, infectious diseases, and immune deficiency are also disclosed as are vaccination methods. The methods comprise administering one or more regulatory compositions to inactivate the T suppressor cells by reducing the acetylation level and/or protein level of FOXP3. Improved vaccines and vaccination methods are disclosed. Methods of identifying compounds that are useful to modulate acetylation level and/or protein level of FOXP3 and treat diseases are disclosed. | 03-11-2010 |
| 20100035806 | Compositions and Methods for Detection and Modulation of T Cell Mediated Immune Responses Against Viral Vectors Utilized for Gene Therapy - Compositions and methods are provided for inhibiting T cell mediated destruction of virally transduced, trangene containing cells. | 02-11-2010 |
| 20090216320 | Magnetic Gradient Targeting And Sequestering Of Therapeutic Formulations And Therapeutic Systems Thereof - A therapeutic system and a method that uses stents, and/or other implantable devices ( | 08-27-2009 |
| 20090216089 | FOOT RETRACTORS - A foot retractor includes an elongated body portion, a handle curving away from the body portion, and a tapered blade portion extending at an angle from the body portion, distal from the handle portion. The blade portion comprises a curvature therein. | 08-27-2009 |
| 20090156565 | COMPOSITION AND USE THEREOF IN ENHANCING A THERAPEUTIC EFFECT OF AN ANTIEPILEPTIC DRUG - A composition and a method for the use of the composition for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal. A composition includes a glucocorticoid receptor antagonist and an antiepileptic drug, wherein the glucocorticoid receptor antagonist is present in an amount effective to enhance a therapeutic effect of the antiepileptic drug in treating a seizure in a status-epilepticus in an animal. A method of use of a glucocorticoid receptor antagonist for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal, the method includes administering the glucocorticoid receptor antagonist and the antiepileptic drug, wherein the glucocorticoid receptor antagonist is administered to the animal prior to, contemporaneous with, or subsequent to administering the antiepileptic drug in an amount effective to enhance the therapeutic effect of the antiepileptic drug. | 06-18-2009 |
| 20090082611 | Uniform field magnetization and targeting of therapeutic formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles. | 03-26-2009 |
| 20090010984 | STEROID LIPID-MODIFIED POLYURETHANE AS AN IMPLANTABLE BIOMATERIAL, THE PREPARATION AND USES THEREOF - A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial. | 01-08-2009 |
| 20080317761 | Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage - A pharmaceutical composition comprises a therapeutic peptide or protein, a transport moiety capable of transporting said first peptide or protein into a hematopoietic cell differentiated from a common myeloid progenitor, and a linker between said first protein and said transport moiety, said linker susceptible to cleavage by an intracellular enzyme in the cell. A cell or collection of cells, e.g., platelets, containing such a composition is useful in methods for treating infection, inflammation, vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage. Methods of making such compostions are also disclosed. | 12-25-2008 |
| 20080213222 | Methods And Compositions For Use In Gene Therapy for Treatment of Hemophilia - The invention includes a composition comprising a recombinant adeno-associated viral vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5′ and 3′ untranslated regions and a transcription termination | 09-04-2008 |
